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Abstract
Background: High-amylose maize resistant starch type 2 (HAM-RS2) stimulates gut-derived satiety peptides and
reduces adiposity in animals. Human studies have not supported these findings despite improvements in glucose
homeostasis and insulin sensitivity after HAM-RS2 intake which can lower adiposity-related disease risk. The primary
objective of this study was to evaluate the impact of HAM-RS2 consumption on blood glucose homeostasis in
overweight, healthy adults. We also examined changes in biomarkers of satiety (glucagon-like peptide-1 [GLP-1],
peptide YY [PYY], and leptin) and body composition determined by anthropometrics and dual-energy x-ray
absorptiometry, dietary intake, and subjective satiety measured by a visual analogue scale following HAM-RS2
consumption.
Methods: Using a randomized-controlled, parallel-arm, double-blind design, 18 overweight, healthy adults
consumed either muffins enriched with 30 g HAM-RS2 (n = 11) or 0 g HAM-RS2 (control; n = 7) daily for 6 weeks.
The HAM-RS2 and control muffins were similar in total calories and available carbohydrate.
Results: At baseline, total PYY concentrations were significantly higher 120 min following the consumption of
study muffins in the HAM-RS2 group than control group (P = 0.043). Within the HAM-RS2 group, the area under
the curve (AUC) glucose (P = 0.028), AUC leptin (P = 0.022), and postprandial 120-min leptin (P = 0.028) decreased
independent of changes in body composition or overall energy intake at the end of 6 weeks. Fasting total PYY
increased (P = 0.033) in the HAM-RS2 group, but changes in insulin or total GLP-1 were not observed. Mean overall
change in subjective satiety score did not correlate with mean AUC biomarker changes suggesting the satiety
peptides did not elicit a satiation response or change in overall total caloric intake. The metabolic response from
HAM-RS2 occurred despite the habitual intake of a moderate-to-high-fat diet (mean range 34.5% to 39.4% of total
calories).
Conclusion: Consuming 30 g HAM-RS2 daily for 6 weeks can improve glucose homeostasis, lower leptin
concentrations, and increase fasting PYY in healthy overweight adults without impacting body composition
and may aid in the prevention of chronic disease. However, between-group differences in biomarkers were
not observed and future research is warranted before specific recommendations can be made.
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Introduction
Epidemiological observations show that consuming a diet
high in fiber can lower the risk for obesity, obesity-related
comorbidities, and reduce all-cause mortality [1, 2]. One
systematic review that examined the effects of dietary fiber
on body weight reported that a 0.4% reduction in body
weight can be achieved by consuming most dietary fibers
for 4 weeks [3]. However, the amount of weight lost was
dependent on the physiochemical properties (solubility,
fermentability, and viscosity) of each type of fiber [3].
The purported mechanisms by which fiber contributes
to weight loss such as altering gut motility, attenuating
nutrient absorption, and lowering overall caloric intake
are also associated with the physiochemical properties
[2, 4]. Fermentable fibers are receiving attention because
the metabolites produced from bacterial fermentation in
the gastrointestinal (GI) tract can influence body weight.
These fibers produce short chain fatty acids (SCFA;
acetate, propionate, butyrate) in the distal intestine that
stimulate the release of glucagon-like peptide-1 (GLP-1)
and peptide YY (PYY) that act synergistically with leptin,
an adipokine primarily released from adipose tissue, to
induce satiety and regulate energy expenditure through
central nervous system actions [5–7].
Despite increased SCFA production from fiber fer-
mentation, the relationship between GLP-1 and PYY on
satiety and food intake in humans is inconsistent. After
consuming a standardized breakfast on the morning
immediately following 3 days of consecutive intake of a
barley kernel-based bread with resistant starch, fasting
plasma GLP-1 and postprandial PYY concentrations
increased in healthy middle-aged adults [8]. However,
changes in appetite sensations (satiety, hunger, and de-
sire to eat) did not occur [8]. Similarly, overweight
women did not elicit a postprandial subjective satiety
response despite improvements of GLP-1 and PYY after
consuming an enzyme-hydrolyzed arabinoxylan from
wheat or intact arabinoxylan from flax at breakfast [9]. In
contrast, in healthy adults, the upregulation of GLP-1 and
PYY corresponded with enhanced subjective satiety imme-
diately after resistant maltodextrin intake [10]. However,
subsequent energy intake was not suppressed despite
these improvements. One recent trial found improve-
ments in the area under the curve (AUC) PYY that corre-
sponded with satiety and a 14% reduction in food intake
in healthy adults consuming 15 g unripe banana flour rich
in resistant starch for 6 weeks [11]. The different satiety
peptides and satiation responses may be related to fer-
mentability patterns, the type, amount, and duration of
fiber intake, and the gut microbiota composition of indi-
viduals. Also, blood gut peptides may be too low in con-
centration to cross the blood brain barrier or the
individuals may have hypothalamic resistance, which can
occur from a high-fat diet even in lieu of obesity [12].
High-amylose maize resistant starch type 2 (HAM-RS2)
is an insoluble, nonviscous fermentable fiber that has been
shown to improve glucose homeostasis and/or peripheral
insulin sensitivity among individuals who were healthy
with normal glucose homeostasis [13] or those with meta-
bolic syndrome [14–16]. However, many of these trials of
longer duration did not report or show improvements in
blood concentrations of gut peptides, satiety responses, or
changes in food intake. HAM-RS2 may exert its benefits
on glucose metabolism by increasing SCFA in the blood
to alter free fatty acid and glycerol release from adipocytes
and increased fat oxidation [17], modulate bile acid me-
tabolism [18], or alter the gut microbiota profile [19].
Most previous trials reported the impact of HAM-RS2
on glucose homeostasis in either healthy individuals or
those with metabolic syndrome [12–15]. Therefore, our
primary aim was to determine the impact of the daily con-
sumption of 30 g HAM-RS2 incorporated into muffins for
6 weeks on glucose homeostasis in normoglycemic,
healthy overweight adults at risk for developing glycemic
abnormalities. We also measured fasting and postprandial
biomarker concentrations known to influence satiety
(GLP-1, PYY, and leptin), subjective satiety, dietary intake,
and body composition in these individuals.
Materials and Methods
Participants
Healthy overweight adults with a body mass index (BMI)
≥ 28 kg/m2 between 18 and 50 years of age of any race or
ethnicity were recruited from Denton, Texas and the sur-
rounding area. Participants were sedentary (<20 min of ac-
tivity no more than 2 days per week) for at least 6 months
prior to enrollment in the study. Exclusion criteria in-
cluded those diagnosed with or taking medication(s) for
chronic conditions, such as diabetes, hypertension, cancer,
diseases of the liver, kidney, or heart, or other metabolic
disorders. Participants were also excluded if they gained
or lost a significant amount of weight or followed a special
diet ≤ 3 months prior to enrollment, consumed vitamins,
minerals, or antioxidants in excess of amounts found in a
daily multivitamin tablet, or dietary supplements known
to alter metabolism, had an intolerance to the study foods,
or smoked. Women who were pregnant, lactating, or in-
terested in becoming pregnant were not eligible. The
study was approved by the Institutional Review Board at
Texas Woman’s University. All participants provided writ-
ten consent prior to study enrollment.
Protocol
The study was a randomized-controlled, parallel-arm,
double-blind design lasting 6 weeks. Individuals who met
the screening criteria and agreed to participate in the
study were randomized to either the HAM-RS2 group or
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control group using a random numbers generator from
SPSS version 19 (IBM Corporation, Armonk, NY, USA).
Prior to participant randomization, the study muffins
were formulated at the University food preparation
laboratory. The treatment muffins were developed to
provide 50 g Hi-Maize® 260 resistant starch (~30 g
HAM-RS2, ~20 g equal mixture slowly and rapidly
digestible starch; Ingredion Incorporated, Westchester,
IL, USA) daily. The control muffins (0 g HAM-RS2)
were developed to contain similar amounts of available
carbohydrate and minimal differences in total calories
than the treatment muffins (Table 1). Each 60 g treat-
ment muffin contained 16.7 g Hi-Maize® 260 resistant
starch to provide 10 g HAM-RS2, therefore three muf-
fins (180 g cooked) were required to obtain 30 g HAM-
RS2 daily as indicated in the protocol. No difference in
overall muffin likeability was found based on sensory
evaluations of HAM-RS2 and control muffins using a
9-point hedonic scale prior to the implementation of
this study [20]. All study muffins were prepared, pack-
aged, and labeled by culinary and nutrition students
twice per week to ensure freshness and quality. Two
flavors of the treatment and control muffins were de-
veloped, pumpkin spice and cranberry spice. The differ-
ent flavors of muffins were administered on alternating
weeks to alleviate monotony and improve compliance.
The two flavors of muffins were closely matched for total
calories and macronutrients. The cranberry spice muffins
included 4.3 g dried cranberries, but no pumpkin puree.
The pumpkin spice muffins included 6.8 g pumpkin puree
without dried cranberries. Different amounts of dried
cranberries and pumpkin puree were added so the caloric
value of each muffin type was similar.
The participants arrived for baseline data collection
following an overnight fast. Anthropometric measure-
ments were obtained in triplicate followed by the base-
line blood collection (time 0). Participants consumed
all three of their respective study muffins within 15 min
along with 6 oz of orange juice. Immediately following
muffin intake the participants completed a visual analogue
scale (VAS). Four additional postprandial blood samples
were collected at 15, 30, 60, and 120 min. Nutrition
education and body composition analysis occurred
between blood collections. Participants were instructed by
a Registered Dietitian Nutritionist (RDN) to follow a
balanced diet according to the Dietary Guidelines for
Americans 2010 [21] adjusted for the caloric value of
the study muffins and to remain sedentary during the
study. Body composition was determined by whole
body dual-energy x-ray absorptiometry (DXA) using
the Lunar DPX NT model (GE Healthcare, Fairfield,
CT, USA). Body composition analysis and blood collec-
tions were repeated using the same protocol as baseline
at the end of the intervention (week 6).
Dietary intake and bowel habits
Three days prior to baseline measurements, at midpoint
(week 3), and the end of the study (week 6) all participants
completed bowel habit logs and dietary intake journals for
3 days as instructed by a RDN. Dietary intake was ana-
lyzed using the United States Department of Agriculture
National Nutrient Database for Standard Reference [22].
The bowel habit logs evaluated tolerance and potential ad-
verse events from study muffin consumption by asking a
series of questions adapted from Lewis et al. [23], such as
“describe the consistency of your stools,” and provided a
space for comments. Participants were instructed to con-
tact investigators immediately if abnormal changes in
bowel habits, or the presence of blood or mucus, were ob-
served. Muffin intake compliance was assessed through
food intake journals.
Subjective satiety measurements
Each VAS was 100 mm in length with questions at each
end to indicate feelings of subjective satiety ranging from
“not at all” to “very much or a lot”. The 7 questions were
adapted from Flint et al. [24] and included “how hungry
are you?”, “how satisfied do you feel?”, “how full do you
feel?”, “how much do you think you can eat?”, “how
pleasant would you find eating another mouthful of this
food?” “would you like to eat something sweet?”, and
“would you like to eat something fatty?”.
Biomarkers
A phlebotomist drew approximately 12 mL of blood at
each time point into EDTA vacutainers (BD Diagnos-
tics, Franklin Lakes, NF, USA). The tubes were centri-
fuged at 3,200 rpm for 12 min at 4 °C. Plasma was
immediately aliquoted into 1.5 mL Eppendorf micro-
centrifuge tubes and stored at −80 °C until analyzed
for glucose, insulin, GLP-1, PYY, and leptin. Glucose
was determined using a hexokinase colorimetric
method (Stanbio Laboratory, Boerne, TX, USA) with
Table 1 Comparison of nutrients between muffinsa
Nutrient HAM-RS2 Control
Energy (kcal)b 349.6 389.1
Available carbohydrate (g)c 70.5 71.6
Protein (g) 5.4 10.6
Fat (g) 5.1 6.6
Fiber (g) 30.9 11.4
aNutrient analysis based on the amount consumed daily by each participant;
180 g cooked (baked) weight. Analysis conducted by Pope Labs, Irving, Texas
using the following Official AOAC Methods: moisture 925.10; oil 923.03; ash
923.03; nitrogen 988.05A; total dietary fiber 991.43
bEnergy does not include contribution from short chain fatty acids associated
with fermentation
cAvailable carbohydrate excludes fiber
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an intra-assay coefficient of variation (CV) <6%. Total
insulin (CV < 8%; Alpco, Salem, NH, USA), leptin (CV <
6%; Raybiotech, Norcross, GA, USA), and total PYY
(PYY(1–36) and PYY (3–36); CV < 6%; EMD Millipore, Biller-
ica, MA, USA) were measured using an enzyme-linked
immunosorbent (ELISA) technique. Total GLP-1 (GLP-
1(7–36) and GLP-1 (9–36); CV < 7%; Raybiotech, Norcross,
GA, USA) concentrations were determined by an enzyme
immunoassay protocol.
Statistical analysis
To assess differences between and within the HAM-RS2
and control groups, change from mean baseline and final
scores were calculated for anthropometric, body compos-
ition, satiety (after three questions were reverse coded),
and biomarker concentrations from each individual blood
collection time points (fasting, 15, 30, 60, and 120 min).
Due to limited sample size and potential deviations
from normality, primary analyses were conducted using
nonparametric tests. The Wilcoxon Signed Ranked test
compared differences within groups, while the Mann–
Whitney U test examined between group differences.
The total area under the curve (AUC) was calculated
for all plasma biomarkers using the trapazoidal rule and
was compared using the nonparametric tests described
above. Pearson’s correlation coefficient examined associa-
tions between dependent outcomes. Data are presented as
mean ± standard error of the mean (SEM), unless other-
wise noted. SPSS version 19 (IBM Corporation, Armonk,




Twenty-five participants were enrolled in the study;
however, only 18 (83% female) completed the protocol
and were included in the data analysis (Fig. 1). Baseline
characteristics of the participants who completed the
study and were included in the data analysis did not differ
between groups (Table 2).
Dietary intake and compliance
Energy and macronutrient (carbohydrate, protein, lipid)
intake were similar between groups throughout the
study (Table 3). Mean daily fiber intake significantly in-
creased by 113% at midpoint in the HAM-RS2 group. At
week 6, the mean fiber intake in the HAM-RS2 group
increased 100% from baseline indicating fiber intake was
sustained throughout the study. In contrast, the control
group had a significant reduction in both fiber and
carbohydrate intake from midpoint to the end of the
study. Dietary fiber intake was considerably higher in the
HAM-RS2 group at midpoint and the end of the study
than the control. An unexplained reduction in dietary
carbohydrate and fiber intake occurred from week 3 to
week 6 in the control group. At baseline the HAM-RS2
group consumed a high fat diet averaging 95.8 ± 29.5 g/d
(39.3% of total calories), which was non-significantly re-
duced to 82.1 ± 25.1 g/d (34.8% of total calories) at week
6. Based on data from the food intake journals, the
HAM-RS2 and control groups consumed 94 and 98% of
the study muffins, respectively, at midpoint suggesting
high compliance. Compliance decreased to 85% in the
HAM-RS2 group and 73% in the control group at the
end of the study.
Tolerance to study muffins
In both groups, stool consistency was relatively stable
throughout the study. No differences in reaching the
bathroom in time, usage of toilet paper, or marks on
undergarments occurred across groups at any time
point. One participant in the HAM-RS2 group re-
corded the presence of blood or mucus in stool on two
separate occasions; one prior to receiving the
Fig. 1 Consort Diagram
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intervention and the other at midpoint. This participant
was 89% compliant with muffin consumption at mid-
point based on food records suggesting intake remained
adequate. Overall, the HAM-RS2 and control muffins
were well tolerated and few changes in bowel habit in-
dicators were documented throughout the study.
Subjective satiety
Mean overall satiety score did not differ within or between
groups (P = 0.230). The mean score for the question “how
full do you feel?” in the HAM-RS2 group increased from
baseline to the end of the study and approached signifi-
cance (P = 0.058) (data not shown).
Body composition
Consuming muffins with HAM-RS2 did not significantly
change body composition. A decrease (P = 0.043) in total
trunk mass and a near significant decrease in lean trunk
mass (P = 0.063) occurred in the control group (data not
shown). At baseline the HAM-RS2 group had higher
total leg mass (P = 0.011) than the control group, and
the difference was sustained at the end of the interven-
tion (P = 0.02) (data not shown).
Biomarkers
Changes from baseline to week 6 in the AUC for the
plasma biomarkers are shown in Table 4. At the end of
the 6-week treatment, the AUC change from baseline
was not significantly different between HAM-RS2 and
control groups for any biomarker measures. However, a
significant within-group decrease in both AUC glucose
(P = 0.028) and AUC leptin (P = 0.022) was observed
from baseline to week 6 in the HAM-RS2 group. There
were no changes from baseline to the end of the interven-
tion in the AUC for any biomarker in the control group.
Within-group comparisons for biomarkers collected at
each time point at the end of the intervention are shown
in Fig. 2. Only one biomarker differed between groups
Table 2 Baseline participant characteristics
Characteristic HAM-RS2 (n = 11) Control (n = 7) P valuea
Female, n (%) 9 (81.8) 6 (85.7)
Age, years 31.0 ± 3.0 31.2 ± 4.2 0.973
Body mass index (kg/m2) 34.8 ± 1.5 30.6 ± 1.5 0.085
Waist circumference (cm) 99.1 ± 3.7 91.6 ± 3.3 0.151
Total body fat mass (kg)b 42.8 ± 3.1 34.6 ± 3.0 0.085
Total body lean mass (kg)b 47.3 ± 1.8 43.7 ± 2.3 0.179
Trunk total mass (kg)b 47.1 ± 3.6 43.9 ± 6.0 0.285
Trunk fat mass (kg)b 22.2 ± 2.1 19.8 ± 3.0 0.285
Trunk lean mass (kg)b 23.8 ± 1.8 23.1 ± 2.9 0.479
Android fat (kg)b 50.8 ± 2.1 50.1 ± 0.8 0.791
Gynoid fat (kg)b 52.2 ± 2.6 49.6 ± 1.0 0.285
Visceral adipose tissue (in3)b 76.8 ± 13.9 63.0 ± 18.1 0.417
Data presented as mean ± SEM except for qualitative values. All body composition measurements were obtained in triplicate after fasting for ≥8 h
aBetween group differences determined by Mann–Whitney U test
bMeasured by dual-energy x-ray absorptiometry (Lunar DPX NT model, GE Healthcare, Fairfield, CT, USA)
Table 3 Changes in mean macronutrient intake between HAM-RS2 and control groups1,2
Nutrient HAM-RS2 Control P value**
Baseline Week 3 Week 6 Baseline Week 3 Week 6
Calories 2190 ± 564 2193 ± 397 2123 ± 424 2091.1 ± 455.3 2046. ± 1337 1910.5 ± 648.7 0.256
Carbohydrate (g) 257.5 ± 84.8 283.0 ± 73.2 268.7 ± 62.6 294.3 ± 90.4 289.4 ± 173.7a 261.7 ± 84.0a 1.000
Protein (g) 82.7 ± 15.3 78.0 ± 13.2 78.4 ± 24.7 88.0 ± 11.1 74.8 ± 48.3 67.4 ± 32.7 0.462
Lipid (g) 95.8 ± 29.5 82.5 ± 20.7 82.1 ± 25.1 75.5 ± 23.9 70.1 ± 52.4 70.8 ± 27.0 0.462
Fiber (g) 21.5 ± 13.9a,b 45.7 ± 8.21* 43.1 ± 6.7b 29.5 ± 14.5 30.2 ± 18.0a* 23.8 ± 6.8a 0.001
1Dietary analysis software used is United States Department of Agriculture (USDA) National Nutrient Database for Standard Reference (http://ndb.nal.usda.gov)
2Within group values with the same letter superscript (a,b) in the same row are statistically different (P < 0.05)
*Between group values are statistically different (P < 0.05) by Mann–Whitney U test
**Between group comparisons at week 6 analyzed by Mann–Whitney U test
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when examining single blood collection time points. The
120 min postprandial concentration of PYY (P = 0.043)
was higher in the HAM-RS2 group than the control group
at baseline. Within-group differences in leptin and PYY
were found from baseline to week 6 in the HAM-RS2
group. A decrease in postprandial leptin (P = 0.028)
occurred at 120 min in the HAM-RS2 group. A within-
group change in PYY was also observed in the HAM-RS2
group where fasting concentrations increased (P = 0.033)
from baseline to the end of the intervention. Within the
control group, no differences in the individual time points
or AUC for any biomarker occurred.
Table 4 Mean AUC biomarker comparisons within and between groups
Biomarkers HAM-RS2 Control P value1
Change from baseline to week 6 P value2 Change from baseline to week 6 P value2
Glucose −1588 ± 545 0.028 −790 ± 706 0.310 0.285
Insulin −908 ± 941 0.333 518 ± 1197 1.000 0.425
GLP-1 120 ± 94 0.139 208 ± 127 0.176 0.791
PYY 438 ± 719 0.285 954 ± 1465 0.866 0.085
Leptin −664 ± 235 0.022 −191 ± 230 0.398 0.425
Data presented as mean ± SEM
1Between group comparisons at week 6 by Mann–Whitney U test
2Within group comparisons from baseline to week 6 by Wilcoxon Signed-Ranked test
Fig. 2 Change in biomarker concentrations from baseline to week 6 in the HAM-RS2 and control groups. This figure shows within-group comparisons
from Wilcoxon Signed Ranked tests and between-group comparisons from Mann–Whitney U tests. aIndicates significant within-group changes in
biomarkers from baseline to week 6. Fasting PYY increased (P = 0.033) while leptin decreased (P = 0.028) 120 min after study foods were consumed in
the HAM-RS2 group. A near-significant decrease (P = 0.062) in leptin also occurred 60 min after study foods were consumed in the HAM-RS2
group. bIndicates significant difference at baseline between groups in 120 min postprandial PYY concentrations (P = 0.043)
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Relationship between subjective satiety and biomarkers
of satiety
Correlations between the mean AUC for each biomarker
and the mean score for each VAS question were not
found in either the control or HAM-RS2 group at the
end of the intervention; however, correlations between
body composition measurements and the AUC for several
biomarkers were found. In the HAM-RS2 group, BMI
(r = 0.655; P = 0.029), percent total fat (r = .889; P <
0.001), total trunk mass (r = 0.851; P = 0.001); trunk fat
(r = 0.700; P = 0.017); trunk lean (r = 0.795; P = 0.003)
were associated with the AUC glucose. The percent
total body fat correlated (r = 0.652; P = 0.030) with AUC
leptin. In the control group AUC glucose was associ-
ated with BMI (r = 0.814; P = 0.026), total fat (r = 0.801;
P = 0.030), percent fat (r = 0.879; P = 0.009), and percent
trunk fat (r = 0.772; P = 0.042). Total trunk lean mass
correlated with the AUC insulin (r = 0.792; P = 0.034) in
the control group. The AUC glucose was associated
with the AUC insulin in both the HAM-RS2 (r = 0.710;
P = 0.014) and control (r = 0.785; P = 0.036) groups.
Discussion
Our primary aim was to examine changes in glucose
homeostasis after consuming 30 g HAM-RS2 for 6 weeks
in overweight adults. We also measured the plasma bio-
markers (GLP-1, PYY, and leptin) and subjective satiety
which could alter dietary intake and body composition.
We found significant reductions in AUC glucose and
AUC leptin in the HAM-RS2 group although differences
between groups did not occur. In addition, a significant
increase in fasting PYY occurred within the HAM-RS2
group after consuming the treatment muffins for 6 weeks.
Interestingly, the favorable changes in biomarkers in the
HAM-RS2 group did not elicit changes in overall mean
subjective satiety score or body composition at the end of
the intervention. Only one biomarker differed between
groups throughout the duration of the study. Baseline
PYY 120-min post-muffin intake was significantly higher
in the HAM-RS2 group which may be attributed to initial
HAM-RS2 fermentation. Increasing the duration of the.
intervention or sample size may have produced additional
between-group changes in biomarkers.
The decrease in AUC glucose in the HAM-RS2 group
occurred under normoglycemic conditions and no
change in overall mean carbohydrate intake suggesting
other contributing mechanisms. One mechanism could
be due to the SCFA produced from the fermentation of
HAM-RS2 by bacteria in the lower GI tract. Butyrate
and propionate are substrates for intestinal gluconeogen-
esis [25]. The newly synthesized glucose from the intes-
tine reduces overall hepatic gluconeogenesis through
portal vein sensors that contribute to overall blood glu-
cose control [25].
Interestingly, HAM-RS2 lowered glucose AUC in the
presence of a high-fat diet. At baseline habitual dietary
fat intake in the HAM-RS2 group was 39.4% of total
calories (~95 g per day). It is well established that diets
high in fat consisting of large amounts of saturated and
omega-6 polyunsaturated fatty acids and lower omega-3
polyunsaturated fatty acids contribute to chronic in-
flammation [26] and the development of chronic dis-
ease. Interestingly when dietary composition contains
only 30.4% of calories from fat, HAM-RS2 can suppress
inflammation and normalize glucose by mediating glu-
coneogenesis potential and altering hepatic fuel usage
from lipids to carbohydrate [27]. Despite observing an
improvement in AUC glucose in the HAM-RS2 group,
we did not see changes in plasma insulin or insulin sensi-
tivity (determined by Homeostasis Model Assessment es-
timates) that have been reported in human trials [13–15].
We did, however, observe a positive correlation between
AUC glucose and AUC insulin in both groups.
A novel finding from our study is that AUC leptin
significantly decreased from baseline to the end of the
intervention in the HAM-RS2 group independent of
changes in body composition. We also found a
significant postprandial reduction at 120 min and near
significant postprandial reductions at 30 (P = 0.074) and
60 min (P = 0.062) in leptin. Leptin is primarily pro-
duced by adipocytes and blood concentrations correlate
with adipocyte size and percent body fat. One plausible
mechanism could be enhanced fat oxidation which has
been observed in healthy adults where postprandial fat
oxidation increased 23% after 5.4% of dietary carbohy-
drate, but not 10.7%, was consumed acutely as HAM-RS2
[17]. Approximately 11% of mean daily carbohydrate in-
take was in the form of HAM-RS2 in our study; how-
ever, our population and study duration differed from
Higgins et al. [17]. Another study found increased fat
oxidation when resistant starch type 4 (RS4) plus whey
protein was administered to healthy overweight and
lean women [28]. Increased fat oxidation and resting
energy expenditure also occurred in healthy lean males
following consumption of 38 g RS4 in a mixed meal
[29]. In addition, a fermentable cereal fiber reduced
leptin by enhancing the gene expression of several en-
zymes involved in fat oxidation [30]. Similar to our
findings, So et al. [31] reported lower leptin in addition
to smaller adipocyte size in mice consuming HAM-RS2
compared to mice on a low resistant starch diet even
though body composition did not differ between the
groups. In contrast, no change in adipose leptin mRNA
expression or plasma leptin concentrations occurred
after a meal tolerance test in healthy males who con-
sumed 30 g HAM-RS2 over 4 weeks [13]. The study by
Robertson et al. examined healthy individuals with an
average BMI of 23.7 kg/m2 which is much lower than
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our mean baseline BMI of 34.8 kg/m2, and our inter-
vention was longer in duration. This suggests that
duration of HAM-RS2 consumption and degree of
adiposity may also be important in modulating leptin.
Differences in adiposity (mean total body fat mass) be-
tween HAM-RS2 and control groups (P = 0.085) may
explain why leptin did not differ between groups in our
study, or that changes in leptin are more sensitive in in-
dividuals with higher fat mass.
The reduction in leptin after HAM-RS2 intake may
benefit individuals with leptin resistance. Leptin resist-
ance can develop from consuming high fat diets [12, 32]
and sustained elevated leptin concentrations [33]. In our
study, the HAM-RS2 group had a mean fasting leptin
concentration of 33 ± 6 ng/mL. Fasting leptin concentra-
tions of ≥15 ng/mL have been described as the cutoff
value to predict insulin resistance [34]. Although we did
not observe insulin resistance in the HAM-RS2 group, it
is plausible that the study participants in our study were
resistant to leptin due to high blood leptin concentra-
tions and consumption of a high-fat diet at baseline. We
observed significant reductions in leptin, but also a non-
significant mean reduction (5.5%) in total calories from
fat, but not overall total calories, in the HAM-RS2
group. This decrease in dietary fat is not likely respon-
sible for the decrease in AUC leptin concentrations [35].
Similar to our results, leptin decreased with the addition
of a fermentable soluble fiber in obese rats ingesting a
high-fat diet [36]. Interestingly, the decrease in leptin in
this study did not induce an orexigenic effect since over-
all caloric intake did not change and was similar to the
control.
Our study also found an increase in total fasting PYY
but not postprandial or AUC PYY in the HAM-RS2
group at the end of the study. The increase may be re-
lated to the carry-over fermentation effects of prior-day
HAM-RS2 intake. Increased PYY has been observed
with fermentable fiber consumption in animal studies
[37]. PYY binds to the Y2 receptors of the arcuate nu-
cleus to elicit a satiation response alongside increased
energy expenditure [38]. Two isoforms of PYY exist:
PYY1–36 and PYY3–36. PYY1–36 predominates under
fasting conditions and has a lower affinity to the Y2 re-
ceptor. This may explain why we did not see a relation-
ship between total PYY and satiety. At baseline, PYY
was significantly higher (P = 0.043) in the HAM-RS2
group than control 120 min after the consumption of
the study muffins and may be due to the initial fermen-
tation of HAM-RS2 following intake. A similar increase
in PYY occurred in healthy adults consuming resistant
starch and whey protein 180 min after intake [28]. We
did not observe improvements in GLP-1, which is con-
sistent with several human studies examining HAM-
RS2 intake in overweight adults for ≥4 weeks [39, 40].
This study has several limitations. First, only inactive
concentrations of GLP-1 and total PYY (PYY(1–36) +
PYY(3–36)) were measured. We were not able to determine
the exact PYY isoform which may have explained why
subjective satiety did not change. Another limitation in-
cludes the lack of adding di-peptidyl peptidase-4 inhibitors
(DPP-IV) following blood collection. DPP-IV rapidly de-
grades GLP-1, thus we were not able to measure the
physiologically active form of GLP-1 [41]. Also, the par-
ticipants consumed the study muffins at any time dur-
ing the day. Consuming the muffins at one meal or
equally distributed throughout the day could impact
metabolic response. In addition, the participants con-
sumed the study muffins prior to postprandial blood
collection instead of an isocaloric mixed meal equal in
macronutrient composition. Thus, the plasma bio-
marker response is reflective of study muffin consump-
tion. However, a between group 120-min improvement
in PYY was observed in the HAM-RS2 group indicating
fermentation can upregulate this satiety peptide. Lastly,
a significant reduction in daily fiber intake from mid-
point to week 6 occurred in the control group indicat-
ing the control muffins replaced other high-fiber foods
in the diet.
Conclusion
In conclusion, daily consumption of 30 g of HAM-RS2 in
muffins over 6 weeks can decrease leptin concentrations,
assist with blood glucose homeostasis, and improve fasting
PYY in healthy overweight adults. These findings occurred
without changes in total caloric intake or body compos-
ition. Adding HAM-RS2 to the diet can improve fiber in-
take to enhance overall diet quality. However, strong
conclusions cannot be made due to small sample size and
between group differences in biomarkers were not ob-
served at the end of the intervention. The mechanisms as-
sociated with biomarker changes in the HAM-RS2 group
are likely related to the fermentation of HAM-RS2 by gut
microbiota, but additional research is needed to determine
the type, amount, and duration of resistant starch that
would provide the most advantageous physiological
results.
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